New Serco CEO Soames marks arrival with large share purchase
6th May 2014 15:51
Rupert Soames, who last week took up the role of Chief Executive Officer at embattled Serco Group, has given a show of faith in his own leadership - and taken advantage of the latest dip in its share price - with the purchase of 242,000 shares at 354.30p a share. The £857,406 deal gives a show of f
Read moreSinclair IS Pharma non-execs subscribe for placing shares
2nd May 2014 15:55
Stuart Swanson, a non-executive director of AIM-listed Sinclair IS Pharma on Friday subscribed for just under 3.13m shares as part of a placing that was on Thursday approved by shareholders to support the acquisition of Silhouette, an aesthetics company. The deal followed a purchase made earlier
Read moreSinclair IS Pharma CEO grows stake to 8.75m shares
1st May 2014 15:49
The Chief Executive Officer (CEO) of AIM-listed Sinclair IS Pharma this week added 285,844 to his stake, while fellow board member Stuart Swanson made the modest purchase of 12,774 shares. CEO Chris Spooner paid 30.88p, spending a total of £106,047. His shareholding in the pharmaceutical group now
Read moreThorntons board grow stakes as investors sell on poor Q3
30th Apr 2014 15:37
The Chief Executive and Finance Director of chocolatier Thorntons each purchased 20,000 shares in the group on Wednesday after it reported a softening of third quarter sales. Jonathan Hart, the group's Chief Executive, paid 120.50p a share spending a total of £24,100 and taking his total stake to 2
Read moreQuindell board members stock up
28th Apr 2014 15:52
Software and technology outsourcing group Quindell on Monday announced share purchases by three of its board members following its decision to start legal proceedings against a short-seller at the end of last week. Rob Terry, the firm's founder and Executive Chairman, bought a stake worth £95,000
Read moreSinclair IS Pharma gains full distribution rights for Perfectha
25th Apr 2014 13:50
Sinclair IS Pharma has completed the acquisition of the distribution rights for dermal filler product Perfectha in Brazil and Russia. The rights, which were bought from Pharmavital SA for £5.7m, represent two times Pharmavital's 2013 sales. The move gives Sinclair worldwide rights to Perfectha.
Read moreMiton director builds stake following year of 'significant' organic growth
22nd Apr 2014 15:42
David Barron, the Director of Investment Trusts and Product Strategy at Miton Group, an AIM-listed fund management company, has purchased 280,000 group shares. Barron spent 45.58p on each of the shares, spending a total of £127,624. The deal comes a month after the firm posted said annual pre-tax
Read moreWednesday broker round-up UPDATE
16th Apr 2014 08:44
Afren: Investec cuts target price from 200p to 195p and stays with its buy recommendation. Alexander Mining: Northland lowers target price from 8.1p to 6.1 and maintains a buy recommendation. Capita Group: JP Morgan ups target price from 1261p to 1279p and maintains an overweight rating. Central
Read moreSinclair IS Pharma reduces half-year losses
25th Mar 2014 08:08
- Trims half-year losses - Expects full-year to meet targets - Confident about future progress AIM-listed speciality pharmaceutical company Sinclair IS Pharma reduced half year pre-tax losses by a half and said it remained confident about future progress. Pre-tax losses reduced to £2.5m for the si
Read moreSinclair IS Pharma acquires derma filler company
31st Jan 2014 12:44
Sinclair IS Pharma, a speciality AIM-listed pharmaceutical company, has acquired dermal filler firm Atlean for an undisclosed cash consideration. Atlean, which used a combination of collagen stimulator and hyaluronic acid filler particularly for the treatment of the lower face, was acquired as a c
Read moreTuesday broker round-up UPDATE
21st Jan 2014 08:17
BG Group: Credit Suisse ups target price from 1170p to 1200p, while leaving its underperform rating unchanged. BHP Billiton: UBS lowers target price from 2090p to 2060p, while its buy recommendation is kept. Diageo: UBS cuts target price from 2050p to 2000p maintaining a neutral rating. DP World
Read moreSinclair IS Pharma takes a hit but stays confident for full year
16th Jan 2014 13:44
Shares in AIM 100 group Sinclair IS Pharma took a hit as the company reported a mixed trading update for the first half of its financial year, however analysts reiterated their optimism. Growth was held back in the period, with like-for-likes down 7% even though revenues rose 6.5% to £24.5m in the
Read moreThursday broker round-up UPDATE
16th Jan 2014 08:59
Aberdeen Asset Management: Canaccord Genuity cuts target price from 586p to 540p, while its buy recommendation remains unchanged. Anglo American: UBS ups target price from 1500p to 1580p upgrading from neutral to buy. Antofagasta: Investec reduces target price from 716p to 685p maintaining a sell
Read moreBroker tips: Asos, Sinclair, Booker
19th Sep 2013 11:31
Online fashion retailer Asos impressed investors on Thursday as it beat fourth quarter forecasts to wrap up the year in style. The AIM-listed company lifted retail sales 47% to £208m in the fourth quarter to produce a 40% increase to £754m for the full year, supported by rapid growth in Europe and
Read moreBroker snap: Jefferies on Sinclair IS Pharma's full-year results
19th Sep 2013 09:52
Sinclair IS Pharma was issued a 'buy' rating by Jefferies International after reporting a jump in pre-tax profit for the full year 2013. Adjusted profit before tax and exceptional items soared 69% to £4.3m as sales rose 7.7% to £55.4m, driven by aesthetic non-surgical facelift products. "Strong g
Read more